3-(1,3-二氧烷）苯胺 | 168551-56-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(1,3-二氧烷）苯胺
• 中文别名: 3-(1,3-二氧烷)苯胺
• 英文名称: 3-[1,3]dioxan-2-yl-aniline
• 英文别名: 3-[1,3]Dioxan-2-yl-anilin；3-(1,3-dioxan-2-yl)aniline
• CAS: 168551-56-2
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD02853017
• 分子量: 179.219
• InChiKey: LOIMKZYNBRCYDN-UHFFFAOYSA-N

物化性质

• 熔点：
  75 °C
• 沸点：
  141 °C(Press: 1.5 Torr)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 安全说明：
  S26,S36/37/39

SDS

Name:	3-(1 3-Dioxan-2-yl)aniline Material Safety Data Sheet
Synonym:
CAS:	168551-56-2

Section 1 - Chemical Product MSDS Name:3-(1 3-Dioxan-2-yl)aniline Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
168551-56-2	3-(1,3-Dioxan-2-yl)aniline		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Do not store in direct sunlight. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 168551-56-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 74 - 76 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H13NO2
Molecular Weight: 179.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water, direct sunlight..
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 168551-56-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(1,3-Dioxan-2-yl)aniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 168551-56-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 168551-56-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 168551-56-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1,3-二氧烷）苯胺 、 4-fluoro-[1,1'-biphenyl]-3-carbonitrile 在 三甲基铝 作用下， 以 正庚烷 、 甲苯 为溶剂， 反应 3.5h， 生成 N-(3-[1,3]Dioxan-2-yl-phenyl)-4-fluoro-biphenyl-3-carboxamidine
  参考文献：
  名称：

  EP2 RECEPTOR AGONISTS

  摘要：

  公式（III）的化合物：或其盐、溶剂合物和化学保护形式，其中：R5是可选择取代的C5-20芳基或C4-20烷基基团；L′是单键，—O—或—C(═O)—；A选自以下组：式（i）（ii）（iii），其中X和Y选自以下组：O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；和N和O，其中虚线表示适当位置的双键，Q是N或CH；D从以下中选择：式（i）（ii）（iii）（iv）（v）（vii）（viii）（ix）B从以下组中选择：式（A）（B），其中RP6选自氟和氯；R2是：（i）—CO2H；（ii）—CONH2；（iii）—CH2—OH；或（iv）四唑-5-基。

  公开号：

  US20100130556A1
• 作为产物：
  描述：

  2-(m-Nitro-phenyl)-1,3-dioxan 生成 3-(1,3-二氧烷）苯胺
  参考文献：
  名称：

  US2481434

  摘要：

  公开号：

文献信息

• [EN] PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO-QUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE CHOLINE KINASE
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2019011715A1

  公开（公告）日：2019-01-17

  The present invention relates to substituted pyrazolo-quinazoline derivatives which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune- related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明涉及替代吡唑喹唑啉衍生物，其调节胆碱激酶（ChoK）的活性。因此，本发明的化合物在治疗由改变的胆碱代谢引起的疾病方面具有用途，如癌症、细胞增殖异常、不同起源的传染病、免疫相关疾病和神经退行性疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物以及利用包含这些化合物的药物组合物治疗疾病的方法。
• Heterocyclically Substituted Anilinopyrimidines
  申请人：Wasnaire Pierre

  公开号：US20110245249A1

  公开（公告）日：2011-10-06

  Heterocyclically substituted anilinopyrimidines of the formula (I) in which R 1 to R 12 and E1, E2, E3, L 1 , Y, Z and L 2 have the meanings given in the description, and agrochemically active salts thereof, their use and also methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on seed of plants, processes for preparing such compositions and treated seed and also their use for controlling phytopathogenic harmful fungi in agriculture, horticulture and forestry, in the protection of materials and in the domestic and hygiene field. The present invention furthermore relates to a process for preparing heterocyclically substituted anilinopyrimidinenes of the formula (I).

  公式(I)中的杂环取代苯基嘧啶，其中R1至R12和E1、E2、E3、L1、Y、Z和L2具有描述中给出的含义，以及其农用活性盐，它们的用途以及控制植物或种子中和/或植物中和/或植物种子上的植物病原真菌的方法和组合物，用于制备这种组合物的过程以及受处理的种子，以及其在农业、园艺和林业中控制植物病原真菌的用途，在材料保护以及家庭和卫生领域。本发明还涉及制备公式(I)中的杂环取代苯基嘧啶的方法。
• 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use
  申请人：Mann Grace

  公开号：US20090298830A1

  公开（公告）日：2009-12-03

  This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R 1 , R 2 , R 25 , and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及某些JAK-2的嘧啶衍生物抑制剂，具有公式（I）：其中D、E、L、Z、R1、R2、R25和n1如规范中所定义，其药学上可接受的盐，其制药组合物以及其使用方法。
• EP2 receptor agonists
  申请人：Asterand UK Limited

  公开号：US08080567B2

  公开（公告）日：2011-12-20

  A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.

  化合物的化学式(III)：或其盐，溶剂合物和化学保护形式，其中：R5是可选取代的C5-20芳基或C4-20烷基；L'是单键，-O-或-C（=O）-；A选自以下组：公式（i），（ii），（iii），其中X和Y选自以下组：O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；和N和O，其中虚线表示适当位置的双键，Q为N或CH；D选自：公式（i），（ii），（iii），（iv），（v），（vii），（viii），（ix）；B选自以下组：公式（A），（B），其中RP6选自氟和氯；R2为：（i）-CO2H；（ii）-CONH2；（iii）-CH2-OH；或（iv）四唑-5-基。
• [EN] INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12)<br/>[FR] INHIBITEURS DE LA KINASE 12 DÉPENDANTE DE LA CYCLINE (CDK12)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2023091726A1

  公开（公告）日：2023-05-25

  The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

  本发明提供了抑制一个或多个激酶家族（如丝氨酸/苏氨酸激酶，包括一个或多个CDK蛋白家族，特别是CDK12）的化合物。更具体地说，本发明提供了式 (I) 的 CDK12 抑制剂、其药学上可接受的盐和同位素标记的衍生物、含有该化合物/抑制剂的药物组合物，以及它们的合成方法和用于治疗增殖性疾病（如、膀胱癌、乳腺癌、尤文氏肉瘤、胃癌、胃肠道癌、血癌、肺癌（如小细胞肺癌 (SCLC)）、卵巢癌（如、胰腺癌（如胰腺导管腺癌 (PDAC)）、脑癌（如胶质母细胞瘤）或前列腺癌）。增殖性疾病可以是癌症、良性肿瘤或病理性血管生成，本文所述的任何治疗方法或用途都可以包括诊断患者疾病的步骤。在本发明的其他实施方案中，本文所述的组合物（如化合物、药物组合物和含有它们的试剂盒）用于治疗肌营养不良症（1 型或 2 型）。